Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis

Oxaliplatin (OXA), is a third generation platinum drug used as first‐line chemotherapy in colorectal cancer (CRC). Cancer cells acquires resistance to anti‐cancer drug and develops resistance. ATP‐binding cassette (ABC) drug transporter ABCG2, one of multidrug resistance (MDR) protein which can effe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cellular physiology 2018-07, Vol.233 (7), p.5458-5467
Hauptverfasser: Hsu, Hsi‐Hsien, Chen, Ming‐Cheng, Baskaran, Rathinasamy, Lin, Yueh‐Min, Day, Cecilia H., Lin, Yi‐Jiun, Tu, Chuan‐Chou, Vijaya Padma, Viswanadha, Kuo, Wei‐Wen, Huang, Chih‐Yang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 5467
container_issue 7
container_start_page 5458
container_title Journal of cellular physiology
container_volume 233
creator Hsu, Hsi‐Hsien
Chen, Ming‐Cheng
Baskaran, Rathinasamy
Lin, Yueh‐Min
Day, Cecilia H.
Lin, Yi‐Jiun
Tu, Chuan‐Chou
Vijaya Padma, Viswanadha
Kuo, Wei‐Wen
Huang, Chih‐Yang
description Oxaliplatin (OXA), is a third generation platinum drug used as first‐line chemotherapy in colorectal cancer (CRC). Cancer cells acquires resistance to anti‐cancer drug and develops resistance. ATP‐binding cassette (ABC) drug transporter ABCG2, one of multidrug resistance (MDR) protein which can effectively discharge a wide spectrum of chemotherapeutic agents out of cancer cells and subsequently reduce the intracellular concentration of these drugs. Role of ABCG2 and plausible molecular signaling pathways involved in Oxaliplatin‐Resistant (OXA‐R) colon cancer cells was evaluated in the present study. OXA resistant LoVo cells was developed by exposing the colon cells to OXA in a dose‐dependent manner. Development of multi drug resistance in OXA‐R cells was confirmed by exposing the resistance cells to oxaliplatin, 5‐FU, and doxorubicin. OXA treatment resulted in G2 phase arrest in parental LoVo cells, which was overcome by OXA‐R LoVo cells. mRNA and protein expression of ABCG2 and phosphorylation of NF‐κB was significantly higher in OXA‐R than parental cells. Levels of ER stress markers were downregulated in OXA‐R than parental cells. OXA‐R LoVo cells exposed to NF‐κB inhibitor QNZ effectively reduced the ABCG2 and p‐NF‐κB expression and increased ER stress marker expression. On other hand, invasion and migratory effect of OXA‐R cells were found to be decreased, when compared to parental cells. Metastasis marker proteins also downregulated in OXA‐R cells. ABCG2 inhibitor verapamil, downregulate ABCG2, induce ER stress markers and induces apoptosis. In vivo studies in nude mice also confirms the same. Present study was designed to evaluate plausible role of ABCG2, multi drug resistance protein and associated pathway involved in OXA‐R LoVo cells. Our data show that oxaliplatin resistant LoVo colon cells are resistant to oxaliplatin, 5‐FU, and doxorubicin. Multi drug resistance acquired by overexpression of ABCG2 and p‐NF‐κB and downregulation of ER stress protein thereby preventing apoptosis.
doi_str_mv 10.1002/jcp.26406
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1977778963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1977778963</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4196-16215a23495ec492872bacc721696025e80b46eabaa7cc0a08c5143818191a2c3</originalsourceid><addsrcrecordid>eNp1kcFPHCEUxomxqVvtwX_AkHiph1FgGGY46kZtGxMb057J27dswoYdRmC29dK_XaarHkzKhQC_7-O99xFyzNk5Z0xcrHE4F0oytUdmnOm2kqoR-2RW3nilG8kPyKeU1owxrev6IzkQWshWdt2M_L3_A94NHrLrabTJpQw9WlpOGHyIFjN4itNdpGi9T9QlurFLB9ku6dYBBcxuW_Shp2FFL6_mt4LmQMF7u50oev1AUy7eRdovRywyGMKQQ_nsiHxYgU_288t-SH7dXP-cf63u7m-_zS_vKpRcq4orwRsQtdSNRalF14oFILaCK62YaGzHFlJZWAC0iAxYhw2Xdcc7rjkIrA_Jl53vEMPjaFM2G5emdqC3YUyG67asTqu6oKfv0HUYY1-qM4LxaYC61YU621EYQ0rRrswQ3Qbik-HMTKGYEor5F0phT14cx0WZ3Bv5mkIBLnbAb-ft0_-dzPf5j53lM2GDlZQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2019933979</pqid></control><display><type>article</type><title>Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Hsu, Hsi‐Hsien ; Chen, Ming‐Cheng ; Baskaran, Rathinasamy ; Lin, Yueh‐Min ; Day, Cecilia H. ; Lin, Yi‐Jiun ; Tu, Chuan‐Chou ; Vijaya Padma, Viswanadha ; Kuo, Wei‐Wen ; Huang, Chih‐Yang</creator><creatorcontrib>Hsu, Hsi‐Hsien ; Chen, Ming‐Cheng ; Baskaran, Rathinasamy ; Lin, Yueh‐Min ; Day, Cecilia H. ; Lin, Yi‐Jiun ; Tu, Chuan‐Chou ; Vijaya Padma, Viswanadha ; Kuo, Wei‐Wen ; Huang, Chih‐Yang</creatorcontrib><description>Oxaliplatin (OXA), is a third generation platinum drug used as first‐line chemotherapy in colorectal cancer (CRC). Cancer cells acquires resistance to anti‐cancer drug and develops resistance. ATP‐binding cassette (ABC) drug transporter ABCG2, one of multidrug resistance (MDR) protein which can effectively discharge a wide spectrum of chemotherapeutic agents out of cancer cells and subsequently reduce the intracellular concentration of these drugs. Role of ABCG2 and plausible molecular signaling pathways involved in Oxaliplatin‐Resistant (OXA‐R) colon cancer cells was evaluated in the present study. OXA resistant LoVo cells was developed by exposing the colon cells to OXA in a dose‐dependent manner. Development of multi drug resistance in OXA‐R cells was confirmed by exposing the resistance cells to oxaliplatin, 5‐FU, and doxorubicin. OXA treatment resulted in G2 phase arrest in parental LoVo cells, which was overcome by OXA‐R LoVo cells. mRNA and protein expression of ABCG2 and phosphorylation of NF‐κB was significantly higher in OXA‐R than parental cells. Levels of ER stress markers were downregulated in OXA‐R than parental cells. OXA‐R LoVo cells exposed to NF‐κB inhibitor QNZ effectively reduced the ABCG2 and p‐NF‐κB expression and increased ER stress marker expression. On other hand, invasion and migratory effect of OXA‐R cells were found to be decreased, when compared to parental cells. Metastasis marker proteins also downregulated in OXA‐R cells. ABCG2 inhibitor verapamil, downregulate ABCG2, induce ER stress markers and induces apoptosis. In vivo studies in nude mice also confirms the same. Present study was designed to evaluate plausible role of ABCG2, multi drug resistance protein and associated pathway involved in OXA‐R LoVo cells. Our data show that oxaliplatin resistant LoVo colon cells are resistant to oxaliplatin, 5‐FU, and doxorubicin. Multi drug resistance acquired by overexpression of ABCG2 and p‐NF‐κB and downregulation of ER stress protein thereby preventing apoptosis.</description><identifier>ISSN: 0021-9541</identifier><identifier>EISSN: 1097-4652</identifier><identifier>DOI: 10.1002/jcp.26406</identifier><identifier>PMID: 29247488</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>ABCG2 ; Animals ; Apoptosis ; Apoptosis - drug effects ; ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics ; Biomarkers, Tumor - genetics ; Cancer ; cancer stem cell ; Cell Proliferation - genetics ; Chemotherapy ; Colon ; Colon cancer ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - pathology ; Doxorubicin ; Doxorubicin - administration &amp; dosage ; Doxorubicin - adverse effects ; Drug resistance ; Drug Resistance, Neoplasm - genetics ; Endoplasmic Reticulum Stress - genetics ; Exposure ; G2 phase ; Gene expression ; Gene Expression Regulation, Neoplastic - drug effects ; Humans ; In vivo methods and tests ; Inhibitors ; Intracellular signalling ; Markers ; Metastases ; Mice ; mRNA ; multi drug resistance ; Multidrug resistance ; Neoplasm Proteins - genetics ; Oxaliplatin ; Oxaliplatin - administration &amp; dosage ; Oxaliplatin - adverse effects ; Phosphorylation ; Platinum ; Proteins ; Stresses ; Verapamil ; Xenograft Model Antitumor Assays</subject><ispartof>Journal of cellular physiology, 2018-07, Vol.233 (7), p.5458-5467</ispartof><rights>2017 Wiley Periodicals, Inc.</rights><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4196-16215a23495ec492872bacc721696025e80b46eabaa7cc0a08c5143818191a2c3</citedby><cites>FETCH-LOGICAL-c4196-16215a23495ec492872bacc721696025e80b46eabaa7cc0a08c5143818191a2c3</cites><orcidid>0000-0003-2347-0411</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjcp.26406$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjcp.26406$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29247488$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hsu, Hsi‐Hsien</creatorcontrib><creatorcontrib>Chen, Ming‐Cheng</creatorcontrib><creatorcontrib>Baskaran, Rathinasamy</creatorcontrib><creatorcontrib>Lin, Yueh‐Min</creatorcontrib><creatorcontrib>Day, Cecilia H.</creatorcontrib><creatorcontrib>Lin, Yi‐Jiun</creatorcontrib><creatorcontrib>Tu, Chuan‐Chou</creatorcontrib><creatorcontrib>Vijaya Padma, Viswanadha</creatorcontrib><creatorcontrib>Kuo, Wei‐Wen</creatorcontrib><creatorcontrib>Huang, Chih‐Yang</creatorcontrib><title>Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis</title><title>Journal of cellular physiology</title><addtitle>J Cell Physiol</addtitle><description>Oxaliplatin (OXA), is a third generation platinum drug used as first‐line chemotherapy in colorectal cancer (CRC). Cancer cells acquires resistance to anti‐cancer drug and develops resistance. ATP‐binding cassette (ABC) drug transporter ABCG2, one of multidrug resistance (MDR) protein which can effectively discharge a wide spectrum of chemotherapeutic agents out of cancer cells and subsequently reduce the intracellular concentration of these drugs. Role of ABCG2 and plausible molecular signaling pathways involved in Oxaliplatin‐Resistant (OXA‐R) colon cancer cells was evaluated in the present study. OXA resistant LoVo cells was developed by exposing the colon cells to OXA in a dose‐dependent manner. Development of multi drug resistance in OXA‐R cells was confirmed by exposing the resistance cells to oxaliplatin, 5‐FU, and doxorubicin. OXA treatment resulted in G2 phase arrest in parental LoVo cells, which was overcome by OXA‐R LoVo cells. mRNA and protein expression of ABCG2 and phosphorylation of NF‐κB was significantly higher in OXA‐R than parental cells. Levels of ER stress markers were downregulated in OXA‐R than parental cells. OXA‐R LoVo cells exposed to NF‐κB inhibitor QNZ effectively reduced the ABCG2 and p‐NF‐κB expression and increased ER stress marker expression. On other hand, invasion and migratory effect of OXA‐R cells were found to be decreased, when compared to parental cells. Metastasis marker proteins also downregulated in OXA‐R cells. ABCG2 inhibitor verapamil, downregulate ABCG2, induce ER stress markers and induces apoptosis. In vivo studies in nude mice also confirms the same. Present study was designed to evaluate plausible role of ABCG2, multi drug resistance protein and associated pathway involved in OXA‐R LoVo cells. Our data show that oxaliplatin resistant LoVo colon cells are resistant to oxaliplatin, 5‐FU, and doxorubicin. Multi drug resistance acquired by overexpression of ABCG2 and p‐NF‐κB and downregulation of ER stress protein thereby preventing apoptosis.</description><subject>ABCG2</subject><subject>Animals</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Cancer</subject><subject>cancer stem cell</subject><subject>Cell Proliferation - genetics</subject><subject>Chemotherapy</subject><subject>Colon</subject><subject>Colon cancer</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Doxorubicin</subject><subject>Doxorubicin - administration &amp; dosage</subject><subject>Doxorubicin - adverse effects</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Endoplasmic Reticulum Stress - genetics</subject><subject>Exposure</subject><subject>G2 phase</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Neoplastic - drug effects</subject><subject>Humans</subject><subject>In vivo methods and tests</subject><subject>Inhibitors</subject><subject>Intracellular signalling</subject><subject>Markers</subject><subject>Metastases</subject><subject>Mice</subject><subject>mRNA</subject><subject>multi drug resistance</subject><subject>Multidrug resistance</subject><subject>Neoplasm Proteins - genetics</subject><subject>Oxaliplatin</subject><subject>Oxaliplatin - administration &amp; dosage</subject><subject>Oxaliplatin - adverse effects</subject><subject>Phosphorylation</subject><subject>Platinum</subject><subject>Proteins</subject><subject>Stresses</subject><subject>Verapamil</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0021-9541</issn><issn>1097-4652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFPHCEUxomxqVvtwX_AkHiph1FgGGY46kZtGxMb057J27dswoYdRmC29dK_XaarHkzKhQC_7-O99xFyzNk5Z0xcrHE4F0oytUdmnOm2kqoR-2RW3nilG8kPyKeU1owxrev6IzkQWshWdt2M_L3_A94NHrLrabTJpQw9WlpOGHyIFjN4itNdpGi9T9QlurFLB9ku6dYBBcxuW_Shp2FFL6_mt4LmQMF7u50oev1AUy7eRdovRywyGMKQQ_nsiHxYgU_288t-SH7dXP-cf63u7m-_zS_vKpRcq4orwRsQtdSNRalF14oFILaCK62YaGzHFlJZWAC0iAxYhw2Xdcc7rjkIrA_Jl53vEMPjaFM2G5emdqC3YUyG67asTqu6oKfv0HUYY1-qM4LxaYC61YU621EYQ0rRrswQ3Qbik-HMTKGYEor5F0phT14cx0WZ3Bv5mkIBLnbAb-ft0_-dzPf5j53lM2GDlZQ</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Hsu, Hsi‐Hsien</creator><creator>Chen, Ming‐Cheng</creator><creator>Baskaran, Rathinasamy</creator><creator>Lin, Yueh‐Min</creator><creator>Day, Cecilia H.</creator><creator>Lin, Yi‐Jiun</creator><creator>Tu, Chuan‐Chou</creator><creator>Vijaya Padma, Viswanadha</creator><creator>Kuo, Wei‐Wen</creator><creator>Huang, Chih‐Yang</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2347-0411</orcidid></search><sort><creationdate>201807</creationdate><title>Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis</title><author>Hsu, Hsi‐Hsien ; Chen, Ming‐Cheng ; Baskaran, Rathinasamy ; Lin, Yueh‐Min ; Day, Cecilia H. ; Lin, Yi‐Jiun ; Tu, Chuan‐Chou ; Vijaya Padma, Viswanadha ; Kuo, Wei‐Wen ; Huang, Chih‐Yang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4196-16215a23495ec492872bacc721696025e80b46eabaa7cc0a08c5143818191a2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>ABCG2</topic><topic>Animals</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Cancer</topic><topic>cancer stem cell</topic><topic>Cell Proliferation - genetics</topic><topic>Chemotherapy</topic><topic>Colon</topic><topic>Colon cancer</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Doxorubicin</topic><topic>Doxorubicin - administration &amp; dosage</topic><topic>Doxorubicin - adverse effects</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Endoplasmic Reticulum Stress - genetics</topic><topic>Exposure</topic><topic>G2 phase</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Neoplastic - drug effects</topic><topic>Humans</topic><topic>In vivo methods and tests</topic><topic>Inhibitors</topic><topic>Intracellular signalling</topic><topic>Markers</topic><topic>Metastases</topic><topic>Mice</topic><topic>mRNA</topic><topic>multi drug resistance</topic><topic>Multidrug resistance</topic><topic>Neoplasm Proteins - genetics</topic><topic>Oxaliplatin</topic><topic>Oxaliplatin - administration &amp; dosage</topic><topic>Oxaliplatin - adverse effects</topic><topic>Phosphorylation</topic><topic>Platinum</topic><topic>Proteins</topic><topic>Stresses</topic><topic>Verapamil</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hsu, Hsi‐Hsien</creatorcontrib><creatorcontrib>Chen, Ming‐Cheng</creatorcontrib><creatorcontrib>Baskaran, Rathinasamy</creatorcontrib><creatorcontrib>Lin, Yueh‐Min</creatorcontrib><creatorcontrib>Day, Cecilia H.</creatorcontrib><creatorcontrib>Lin, Yi‐Jiun</creatorcontrib><creatorcontrib>Tu, Chuan‐Chou</creatorcontrib><creatorcontrib>Vijaya Padma, Viswanadha</creatorcontrib><creatorcontrib>Kuo, Wei‐Wen</creatorcontrib><creatorcontrib>Huang, Chih‐Yang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cellular physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hsu, Hsi‐Hsien</au><au>Chen, Ming‐Cheng</au><au>Baskaran, Rathinasamy</au><au>Lin, Yueh‐Min</au><au>Day, Cecilia H.</au><au>Lin, Yi‐Jiun</au><au>Tu, Chuan‐Chou</au><au>Vijaya Padma, Viswanadha</au><au>Kuo, Wei‐Wen</au><au>Huang, Chih‐Yang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis</atitle><jtitle>Journal of cellular physiology</jtitle><addtitle>J Cell Physiol</addtitle><date>2018-07</date><risdate>2018</risdate><volume>233</volume><issue>7</issue><spage>5458</spage><epage>5467</epage><pages>5458-5467</pages><issn>0021-9541</issn><eissn>1097-4652</eissn><abstract>Oxaliplatin (OXA), is a third generation platinum drug used as first‐line chemotherapy in colorectal cancer (CRC). Cancer cells acquires resistance to anti‐cancer drug and develops resistance. ATP‐binding cassette (ABC) drug transporter ABCG2, one of multidrug resistance (MDR) protein which can effectively discharge a wide spectrum of chemotherapeutic agents out of cancer cells and subsequently reduce the intracellular concentration of these drugs. Role of ABCG2 and plausible molecular signaling pathways involved in Oxaliplatin‐Resistant (OXA‐R) colon cancer cells was evaluated in the present study. OXA resistant LoVo cells was developed by exposing the colon cells to OXA in a dose‐dependent manner. Development of multi drug resistance in OXA‐R cells was confirmed by exposing the resistance cells to oxaliplatin, 5‐FU, and doxorubicin. OXA treatment resulted in G2 phase arrest in parental LoVo cells, which was overcome by OXA‐R LoVo cells. mRNA and protein expression of ABCG2 and phosphorylation of NF‐κB was significantly higher in OXA‐R than parental cells. Levels of ER stress markers were downregulated in OXA‐R than parental cells. OXA‐R LoVo cells exposed to NF‐κB inhibitor QNZ effectively reduced the ABCG2 and p‐NF‐κB expression and increased ER stress marker expression. On other hand, invasion and migratory effect of OXA‐R cells were found to be decreased, when compared to parental cells. Metastasis marker proteins also downregulated in OXA‐R cells. ABCG2 inhibitor verapamil, downregulate ABCG2, induce ER stress markers and induces apoptosis. In vivo studies in nude mice also confirms the same. Present study was designed to evaluate plausible role of ABCG2, multi drug resistance protein and associated pathway involved in OXA‐R LoVo cells. Our data show that oxaliplatin resistant LoVo colon cells are resistant to oxaliplatin, 5‐FU, and doxorubicin. Multi drug resistance acquired by overexpression of ABCG2 and p‐NF‐κB and downregulation of ER stress protein thereby preventing apoptosis.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29247488</pmid><doi>10.1002/jcp.26406</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-2347-0411</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0021-9541
ispartof Journal of cellular physiology, 2018-07, Vol.233 (7), p.5458-5467
issn 0021-9541
1097-4652
language eng
recordid cdi_proquest_miscellaneous_1977778963
source Wiley Online Library - AutoHoldings Journals; MEDLINE
subjects ABCG2
Animals
Apoptosis
Apoptosis - drug effects
ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics
Biomarkers, Tumor - genetics
Cancer
cancer stem cell
Cell Proliferation - genetics
Chemotherapy
Colon
Colon cancer
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Colorectal Neoplasms - pathology
Doxorubicin
Doxorubicin - administration & dosage
Doxorubicin - adverse effects
Drug resistance
Drug Resistance, Neoplasm - genetics
Endoplasmic Reticulum Stress - genetics
Exposure
G2 phase
Gene expression
Gene Expression Regulation, Neoplastic - drug effects
Humans
In vivo methods and tests
Inhibitors
Intracellular signalling
Markers
Metastases
Mice
mRNA
multi drug resistance
Multidrug resistance
Neoplasm Proteins - genetics
Oxaliplatin
Oxaliplatin - administration & dosage
Oxaliplatin - adverse effects
Phosphorylation
Platinum
Proteins
Stresses
Verapamil
Xenograft Model Antitumor Assays
title Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T19%3A06%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oxaliplatin%20resistance%20in%20colorectal%20cancer%20cells%20is%20mediated%20via%20activation%20of%20ABCG2%20to%20alleviate%20ER%20stress%20induced%20apoptosis&rft.jtitle=Journal%20of%20cellular%20physiology&rft.au=Hsu,%20Hsi%E2%80%90Hsien&rft.date=2018-07&rft.volume=233&rft.issue=7&rft.spage=5458&rft.epage=5467&rft.pages=5458-5467&rft.issn=0021-9541&rft.eissn=1097-4652&rft_id=info:doi/10.1002/jcp.26406&rft_dat=%3Cproquest_cross%3E1977778963%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2019933979&rft_id=info:pmid/29247488&rfr_iscdi=true